The 2022 Syneos Health Dealmakers’ Intentions Survey comes at a unique juncture in our industry’s history. While months of lockdowns, work disruptions and economic uncertainty have had a very real impact, important trends that began before COVID-19, such as venture financing and IPO markets, will continue to contribute to the backdrop for buying and selling in 2022.
To better understand the current landscape of this volatile marketplace, Syneos Health surveyed dealmakers across the industry to assess their intentions for the next 12 months and put these findings into context. This report, the 12th in our series, captures their expectations for deal activity, supply and demand for specific assets and different development stages, pitfalls leading to failure and other factors affecting dealmaking. What lies ahead for dealmaking in the biopharmaceutical industry in 2022?
